Lixivaptan
id:
lixivaptan-276-13003397
title:
Lixivaptan
text:
Lixivaptan (VPA-985) is an orally-active, non-peptide, selective vasopressin 2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. As of December 2021, lixivaptan is in Phase III clinical development for the treatment of Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease. The U.S. Food and Drug Administration (FDA) has granted orphan drug designa
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Lixivaptan
date created:
date modified:
2024-03-11T20:29:05Z
main entity:
{"identifier":"Q6659958","url":"https://www.wikidata.org/entity/Q6659958"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/c/cb/Lixivaptan_structure.svg","width":512,"height":212}
fields total:
13
integrity:
15